|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
�����崯,������ |
|
���� |
| ��������������� | |
|
Ԭ��ϼ |
|
����Ӣ |
|
���� |
| PubMed | |
|
Article by |
|
Article by |
|
Article by |
�����������崯���Ƶ��о���չ
Ԭ��ϼ, ����Ӣ, ����
�й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о��� �Ͼ� 210042
ϵͳӦ����Ƥ�ʼ���һֱ�����ƴ����������崯����Ҫ����,����������ʹ����Ƥ�ʼ��س������϶����Ӧ�������������˺ܶ��������Ʒ���,�ɲ��������Ƥ�ʼ��ص�����,���������Ƽ������ߵ��ڼ���Ѫ���û��Ʒ���������ע�������ȡ����,���ģ����������ٴ�����֤ʵ������ǿЧ��Ƥ�ʼ��ص���Ч�ԡ�
[2] Yancey KB, Egan CA. Pemphigoid: clinical, histologic, immunopathologic, and therapeutic considerations. JAMA, 2000, 284:350-356.
[3] Lebrun-Vignes B, Roujeau JC, Bernard P, et al. Prednisone is more effective than prednisolone metasulfobenzoate in the treatment of bullous pemphigoid. Arch Dermatol, 1999, 135:89-90.
[4] Egan CA, Meadows KP, Zone JJ. Plasmapheresis as a steroid saving procedure in bullous pemphigoid. Int J Dematol, 2000, 39:230-235.
[5] Rzany B, Partscht K, Jung M, et al. Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of,glucocorticosteroids, and old age. Arch Dernatol, 2002,138:903-908.
[6] Grundmann-Kollmann M, Korting HC, Behrens S, et al. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol, 1999, 40:957.
[7] Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol, 1995, 131:193-197.
[8] Bohm M, Beissert S, Schwarz T, et al. Bullous pemphigoid treated with mycophenolate mofetil. Lancet, 1997, 349:541.
[9] Schorlemmer HU, Milbert U, Zeitter D, et al. Cell cycle regulation and inhibition of de novo pyrimidine biosynthesis by leflunomide. Inflamm Res, 1999, 48:S115-116.
[10] Nousari HC, Anhalt GJ. Bullous pemphigoid treated with leflunomide: a novel immunomodulatory agent. Arch Dermatol, 2000, 136:1204-1205.
[11] Hatano Y, Katagiri K, Arakawa S, et al. Successful treatment by double-filtration plasmapheresis of a patient with bullous pemphigoid:effects in vivo on transcripts of several genes for chemokines and cytokines in peripheral blood mononuclear cells. Br J Dermatol, 2003,148:573-579.
[12] Engineer L, Ahmed AR. Role of intravenous immunoglobulin in the treatment of bullous pemphigoid: analysis of current data. J Am Acad Dermatol, 2001, 44:83-88.
[13] Mouthon L, Kaveri SV, Spalter SH, et al. Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol, 1996, 104:3-9.
[14] Spuls PI, Brakman M, Westerhof W, et al. Treatment of generalized bullous pemphigoid with topical corticosteroids. Acta Derm Venereol,1995, 75:89.
[15] Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topicat corticosteroids in patients with bullous pemphigoid. N Engl J Med,2002, 346:321-327.
[16] Fivenson DP, Breneman DL, Rosen GB, et al. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol, 1994, 130:753-758.
[17] Loo WJ, Kirtschig G, Wojnarowska F. Minocycline as a therapeutic option in bullous pemphigoid. Clin Exp Dermatol, 2001, 26:376.